BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 18836717)

  • 1. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
    Moore TV; Lyons GE; Brasic N; Roszkowski JJ; Voelkl S; Mackensen A; Kast WM; Le Poole IC; Nishimura MI
    Cancer Immunol Immunother; 2009 May; 58(5):719-28. PubMed ID: 18836717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination.
    Voelkl S; Moore TV; Rehli M; Nishimura MI; Mackensen A; Fischer K
    Cancer Immunol Immunother; 2009 May; 58(5):709-18. PubMed ID: 18836718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.
    Schaft N; Willemsen RA; de Vries J; Lankiewicz B; Essers BW; Gratama JW; Figdor CG; Bolhuis RL; Debets R; Adema GJ
    J Immunol; 2003 Feb; 170(4):2186-94. PubMed ID: 12574392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.
    Yee C; Savage PA; Lee PP; Davis MM; Greenberg PD
    J Immunol; 1999 Feb; 162(4):2227-34. PubMed ID: 9973498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
    Morgan RA; Dudley ME; Yu YY; Zheng Z; Robbins PF; Theoret MR; Wunderlich JR; Hughes MS; Restifo NP; Rosenberg SA
    J Immunol; 2003 Sep; 171(6):3287-95. PubMed ID: 12960359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
    Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
    J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
    Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
    J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual recognition of a human cytotoxic T-cell clone for melanoma antigens.
    Kubo H; Abe J; Obata F; Nakajima H; Tsunoda M; Ogawa A; Nakayama S; Beck Y; Kohsaka T; Darrow TL; Abdel-Wahab Z; Saida T; Takiguchi M
    Cancer Res; 1996 May; 56(10):2368-74. PubMed ID: 8625313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
    Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
    J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide.
    Meijer SL; Dols A; Jensen SM; Hu HM; Miller W; Walker E; Romero P; Fox BA; Urba WJ
    J Immunother; 2007; 30(5):533-43. PubMed ID: 17589294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
    Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
    Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative TCR:pMHC Dissociation Rate Assessment by NTAmers Reveals Antimelanoma T Cell Repertoires Enriched for High Functional Competence.
    Gannon PO; Wieckowski S; Baumgaertner P; Hebeisen M; Allard M; Speiser DE; Rufer N
    J Immunol; 2015 Jul; 195(1):356-66. PubMed ID: 26002978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
    Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
    Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism.
    Xu S; Koski GK; Faries M; Bedrosian I; Mick R; Maeurer M; Cheever MA; Cohen PA; Czerniecki BJ
    J Immunol; 2003 Sep; 171(5):2251-61. PubMed ID: 12928369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
    Shilyansky J; Nishimura MI; Yannelli JR; Kawakami Y; Jacknin LS; Charmley P; Rosenberg SA
    Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2829-33. PubMed ID: 7511820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell.
    Roszkowski JJ; Yu DC; Rubinstein MP; McKee MD; Cole DJ; Nishimura MI
    J Immunol; 2003 Mar; 170(5):2582-9. PubMed ID: 12594285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
    Kawakami Y; Dang N; Wang X; Tupesis J; Robbins PF; Wang RF; Wunderlich JR; Yannelli JR; Rosenberg SA
    J Immunother; 2000 Jan; 23(1):17-27. PubMed ID: 10687134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
    Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
    Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.